Prospective data demonstrates effective pain relief and improved function in patients with intractable back and leg pain
electroCore’s gammaCore™ chosen by NHS England to be funded by the Innovation and Technology Payment Program to support adoption in the U.K.
Study will assess SynchroMed™ II Intrathecal Drug Delivery System in patients who have weaned off oral opioids
Helping treat patients with debilitating chronic pain and provideingrelief from hard-to-treat neuropathic conditions
Intellis includes the world’s smallest implantable spinal cord stimulator
Physician roundtable suggests SCS should be first port of call in view of opioid health crisis
BurstDR stimulation targets chronic pain patients with a new therapy option designed to provide less pain, less suffering and less therapy maintenance
Full-Body MRI access expands Spinal Cord Stimulation offering and brings customized therapy to more patients suffering from chronic pain
FDA Clears revolutionary tiny device that offers alternative to opioids for chronic pain sufferers
New clearance for use of Quell Relief smartphone app provides unprecedented level of convenience and comfort when usi treat chronic pain
Patient-centric, recharge-free, upgradeable, MR-conditional, the Proclaim™ Elite SCS System targets patients’ quality of life
St. Jude has gained CE mark approval for its Prodigy MRI™ spinal cord stimulation therapy, the first of its kind to offer MRI compatibility and Burst stimulation
New study data points to St. Jude’s Dorsal Root Ganglion stimulator delivering better pain relief than traditional spinal cord stimulation.
St. Jude Medical, Inc., has gained CE Mark approval and announced the European launch of its Invisible Trial System, an app-based and wireless neuromodulation programming system leveraging Apple™ iPod touch™ and iPad mini™ technology.
Nevro Corporation has received approval from the U.S. FDA for its Senza spinal cord stimulation (SCS) system for the treatment of chronic pain.
Try Turns to Buy as St. Jude slots Spinal Modulation’s Axium into its chronic pain portfolio